3rd TPCF Preclinical Symposium Imaging(TPIS 2020)
The path of discovering/designing a molecule to developing a novel drug could take up to an average of 12 years and costs around $1 billion (USD). Preclinical phase is a major step on this path and is the part where scientists perform additional studies on their molecules prior to moving the drug in...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
3rd TPCF Preclinical Symposium Imaging (TPIS 2020) [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Frontiers in Biomedical Technologies - Tehran University of Medical Sciences, 2020, 7(2020), Supple1 |
|---|---|
| Übergeordnetes Werk: |
volume:7 ; year:2020 ; number:Supple1 |
| Links: |
|---|
| Katalog-ID: |
DOAJ064913082 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ064913082 | ||
| 003 | DE-627 | ||
| 005 | 20230309043120.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ064913082 | ||
| 035 | |a (DE-599)DOAJ9fe4ceb7db3f4426954fe316e1b5f67f | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a R855-855.5 | |
| 100 | 0 | |a 3rd TPCF Preclinical Symposium Imaging (TPIS 2020) |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 3rd TPCF Preclinical Symposium Imaging(TPIS 2020) |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The path of discovering/designing a molecule to developing a novel drug could take up to an average of 12 years and costs around $1 billion (USD). Preclinical phase is a major step on this path and is the part where scientists perform additional studies on their molecules prior to moving the drug into clinical studies. Preclinical studies consist of anything ranging from observing efficacy, dosing strategy, safety and toxicological studies and pharmacokinetics and pharmacodynamics. Pharmacodynamics consist of any studies performed in order to understand the relationship between the amount of drug in the body and its biological effect. In summary this means what does the drug do to the body and how potent and efficacious the drug is? In pharmacokinetics we are interested to identify the effect of body on the drug. Therefore, we would be interested in knowing the absorption, distribution, metabolism and excretion of the novel drug. In order to ensure reliability and consistency all of the preclinical results should be complied with the good laboratory practice and are required to be submitted to organization such as FDA before filing for approval of an investigational new drug. Addressing all of the above questions requires time and money but with the rise of cutting-edge technologies such as preclinical imaging, advancement of preclinical studies has excelled. This is due to being able to see in real time and in the same preclinical model the majority of parameters needed to be identified for preclinical phase of drug development. There are numerous dedicated preclinical imaging devices that could be used. These devices consists of Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Computed Tomography (CT), Optical/Fluorescence and Ultrasound imaging. These technologies require advanced engineering and scientific skills for their development, usage and optimization. This suggests that in order to have an enhanced preclinical imaging infrastructure, we would require an advanced multidisciplinary collaboration and network between engineering and sciences. In order to facilitate this, we at Tehran University of Medical Sciences (TUMS) Preclinical Core Facility (TPCF) organized a symposium branded as TPIS (TPCF Preclinical Imaging Symposium). This was our 3rd annual symposium and it was on online platform due to Covid-19 pandemic. The symposium consisted of talks by domestic and international presenters from various disciplines of science and engineering. We are pleased that Frontiers in Biomedical Technology (FBT) is publishing these abstract in their journal. We at TPCF are also inviting the readers of FBT to attend our 4th annual TPIS (for more information visit our website on: www.TPCF.ir). | ||
| 650 | 4 | |a Preclinical Core Facility | |
| 650 | 4 | |a Preclinical Imaging | |
| 653 | 0 | |a Medical technology | |
| 773 | 0 | 8 | |i In |t Frontiers in Biomedical Technologies |d Tehran University of Medical Sciences, 2020 |g 7(2020), Supple1 |w (DE-627)815913818 |w (DE-600)2806579-7 |x 23455837 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2020 |g number:Supple1 |
| 856 | 4 | 0 | |u https://doaj.org/article/9fe4ceb7db3f4426954fe316e1b5f67f |z kostenfrei |
| 856 | 4 | 0 | |u https://fbt.tums.ac.ir/index.php/fbt/article/view/297 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2345-5837 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2020 |e Supple1 | ||
| author_variant |
r t p s i t rtpsit |
|---|---|
| matchkey_str |
article:23455837:2020----::rtcpelnclypsuia |
| hierarchy_sort_str |
2020 |
| callnumber-subject-code |
R |
| publishDate |
2020 |
| allfields |
(DE-627)DOAJ064913082 (DE-599)DOAJ9fe4ceb7db3f4426954fe316e1b5f67f DE-627 ger DE-627 rakwb eng R855-855.5 3rd TPCF Preclinical Symposium Imaging (TPIS 2020) verfasserin aut 3rd TPCF Preclinical Symposium Imaging(TPIS 2020) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The path of discovering/designing a molecule to developing a novel drug could take up to an average of 12 years and costs around $1 billion (USD). Preclinical phase is a major step on this path and is the part where scientists perform additional studies on their molecules prior to moving the drug into clinical studies. Preclinical studies consist of anything ranging from observing efficacy, dosing strategy, safety and toxicological studies and pharmacokinetics and pharmacodynamics. Pharmacodynamics consist of any studies performed in order to understand the relationship between the amount of drug in the body and its biological effect. In summary this means what does the drug do to the body and how potent and efficacious the drug is? In pharmacokinetics we are interested to identify the effect of body on the drug. Therefore, we would be interested in knowing the absorption, distribution, metabolism and excretion of the novel drug. In order to ensure reliability and consistency all of the preclinical results should be complied with the good laboratory practice and are required to be submitted to organization such as FDA before filing for approval of an investigational new drug. Addressing all of the above questions requires time and money but with the rise of cutting-edge technologies such as preclinical imaging, advancement of preclinical studies has excelled. This is due to being able to see in real time and in the same preclinical model the majority of parameters needed to be identified for preclinical phase of drug development. There are numerous dedicated preclinical imaging devices that could be used. These devices consists of Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Computed Tomography (CT), Optical/Fluorescence and Ultrasound imaging. These technologies require advanced engineering and scientific skills for their development, usage and optimization. This suggests that in order to have an enhanced preclinical imaging infrastructure, we would require an advanced multidisciplinary collaboration and network between engineering and sciences. In order to facilitate this, we at Tehran University of Medical Sciences (TUMS) Preclinical Core Facility (TPCF) organized a symposium branded as TPIS (TPCF Preclinical Imaging Symposium). This was our 3rd annual symposium and it was on online platform due to Covid-19 pandemic. The symposium consisted of talks by domestic and international presenters from various disciplines of science and engineering. We are pleased that Frontiers in Biomedical Technology (FBT) is publishing these abstract in their journal. We at TPCF are also inviting the readers of FBT to attend our 4th annual TPIS (for more information visit our website on: www.TPCF.ir). Preclinical Core Facility Preclinical Imaging Medical technology In Frontiers in Biomedical Technologies Tehran University of Medical Sciences, 2020 7(2020), Supple1 (DE-627)815913818 (DE-600)2806579-7 23455837 nnns volume:7 year:2020 number:Supple1 https://doaj.org/article/9fe4ceb7db3f4426954fe316e1b5f67f kostenfrei https://fbt.tums.ac.ir/index.php/fbt/article/view/297 kostenfrei https://doaj.org/toc/2345-5837 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2020 Supple1 |
| spelling |
(DE-627)DOAJ064913082 (DE-599)DOAJ9fe4ceb7db3f4426954fe316e1b5f67f DE-627 ger DE-627 rakwb eng R855-855.5 3rd TPCF Preclinical Symposium Imaging (TPIS 2020) verfasserin aut 3rd TPCF Preclinical Symposium Imaging(TPIS 2020) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The path of discovering/designing a molecule to developing a novel drug could take up to an average of 12 years and costs around $1 billion (USD). Preclinical phase is a major step on this path and is the part where scientists perform additional studies on their molecules prior to moving the drug into clinical studies. Preclinical studies consist of anything ranging from observing efficacy, dosing strategy, safety and toxicological studies and pharmacokinetics and pharmacodynamics. Pharmacodynamics consist of any studies performed in order to understand the relationship between the amount of drug in the body and its biological effect. In summary this means what does the drug do to the body and how potent and efficacious the drug is? In pharmacokinetics we are interested to identify the effect of body on the drug. Therefore, we would be interested in knowing the absorption, distribution, metabolism and excretion of the novel drug. In order to ensure reliability and consistency all of the preclinical results should be complied with the good laboratory practice and are required to be submitted to organization such as FDA before filing for approval of an investigational new drug. Addressing all of the above questions requires time and money but with the rise of cutting-edge technologies such as preclinical imaging, advancement of preclinical studies has excelled. This is due to being able to see in real time and in the same preclinical model the majority of parameters needed to be identified for preclinical phase of drug development. There are numerous dedicated preclinical imaging devices that could be used. These devices consists of Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Computed Tomography (CT), Optical/Fluorescence and Ultrasound imaging. These technologies require advanced engineering and scientific skills for their development, usage and optimization. This suggests that in order to have an enhanced preclinical imaging infrastructure, we would require an advanced multidisciplinary collaboration and network between engineering and sciences. In order to facilitate this, we at Tehran University of Medical Sciences (TUMS) Preclinical Core Facility (TPCF) organized a symposium branded as TPIS (TPCF Preclinical Imaging Symposium). This was our 3rd annual symposium and it was on online platform due to Covid-19 pandemic. The symposium consisted of talks by domestic and international presenters from various disciplines of science and engineering. We are pleased that Frontiers in Biomedical Technology (FBT) is publishing these abstract in their journal. We at TPCF are also inviting the readers of FBT to attend our 4th annual TPIS (for more information visit our website on: www.TPCF.ir). Preclinical Core Facility Preclinical Imaging Medical technology In Frontiers in Biomedical Technologies Tehran University of Medical Sciences, 2020 7(2020), Supple1 (DE-627)815913818 (DE-600)2806579-7 23455837 nnns volume:7 year:2020 number:Supple1 https://doaj.org/article/9fe4ceb7db3f4426954fe316e1b5f67f kostenfrei https://fbt.tums.ac.ir/index.php/fbt/article/view/297 kostenfrei https://doaj.org/toc/2345-5837 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2020 Supple1 |
| allfields_unstemmed |
(DE-627)DOAJ064913082 (DE-599)DOAJ9fe4ceb7db3f4426954fe316e1b5f67f DE-627 ger DE-627 rakwb eng R855-855.5 3rd TPCF Preclinical Symposium Imaging (TPIS 2020) verfasserin aut 3rd TPCF Preclinical Symposium Imaging(TPIS 2020) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The path of discovering/designing a molecule to developing a novel drug could take up to an average of 12 years and costs around $1 billion (USD). Preclinical phase is a major step on this path and is the part where scientists perform additional studies on their molecules prior to moving the drug into clinical studies. Preclinical studies consist of anything ranging from observing efficacy, dosing strategy, safety and toxicological studies and pharmacokinetics and pharmacodynamics. Pharmacodynamics consist of any studies performed in order to understand the relationship between the amount of drug in the body and its biological effect. In summary this means what does the drug do to the body and how potent and efficacious the drug is? In pharmacokinetics we are interested to identify the effect of body on the drug. Therefore, we would be interested in knowing the absorption, distribution, metabolism and excretion of the novel drug. In order to ensure reliability and consistency all of the preclinical results should be complied with the good laboratory practice and are required to be submitted to organization such as FDA before filing for approval of an investigational new drug. Addressing all of the above questions requires time and money but with the rise of cutting-edge technologies such as preclinical imaging, advancement of preclinical studies has excelled. This is due to being able to see in real time and in the same preclinical model the majority of parameters needed to be identified for preclinical phase of drug development. There are numerous dedicated preclinical imaging devices that could be used. These devices consists of Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Computed Tomography (CT), Optical/Fluorescence and Ultrasound imaging. These technologies require advanced engineering and scientific skills for their development, usage and optimization. This suggests that in order to have an enhanced preclinical imaging infrastructure, we would require an advanced multidisciplinary collaboration and network between engineering and sciences. In order to facilitate this, we at Tehran University of Medical Sciences (TUMS) Preclinical Core Facility (TPCF) organized a symposium branded as TPIS (TPCF Preclinical Imaging Symposium). This was our 3rd annual symposium and it was on online platform due to Covid-19 pandemic. The symposium consisted of talks by domestic and international presenters from various disciplines of science and engineering. We are pleased that Frontiers in Biomedical Technology (FBT) is publishing these abstract in their journal. We at TPCF are also inviting the readers of FBT to attend our 4th annual TPIS (for more information visit our website on: www.TPCF.ir). Preclinical Core Facility Preclinical Imaging Medical technology In Frontiers in Biomedical Technologies Tehran University of Medical Sciences, 2020 7(2020), Supple1 (DE-627)815913818 (DE-600)2806579-7 23455837 nnns volume:7 year:2020 number:Supple1 https://doaj.org/article/9fe4ceb7db3f4426954fe316e1b5f67f kostenfrei https://fbt.tums.ac.ir/index.php/fbt/article/view/297 kostenfrei https://doaj.org/toc/2345-5837 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2020 Supple1 |
| allfieldsGer |
(DE-627)DOAJ064913082 (DE-599)DOAJ9fe4ceb7db3f4426954fe316e1b5f67f DE-627 ger DE-627 rakwb eng R855-855.5 3rd TPCF Preclinical Symposium Imaging (TPIS 2020) verfasserin aut 3rd TPCF Preclinical Symposium Imaging(TPIS 2020) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The path of discovering/designing a molecule to developing a novel drug could take up to an average of 12 years and costs around $1 billion (USD). Preclinical phase is a major step on this path and is the part where scientists perform additional studies on their molecules prior to moving the drug into clinical studies. Preclinical studies consist of anything ranging from observing efficacy, dosing strategy, safety and toxicological studies and pharmacokinetics and pharmacodynamics. Pharmacodynamics consist of any studies performed in order to understand the relationship between the amount of drug in the body and its biological effect. In summary this means what does the drug do to the body and how potent and efficacious the drug is? In pharmacokinetics we are interested to identify the effect of body on the drug. Therefore, we would be interested in knowing the absorption, distribution, metabolism and excretion of the novel drug. In order to ensure reliability and consistency all of the preclinical results should be complied with the good laboratory practice and are required to be submitted to organization such as FDA before filing for approval of an investigational new drug. Addressing all of the above questions requires time and money but with the rise of cutting-edge technologies such as preclinical imaging, advancement of preclinical studies has excelled. This is due to being able to see in real time and in the same preclinical model the majority of parameters needed to be identified for preclinical phase of drug development. There are numerous dedicated preclinical imaging devices that could be used. These devices consists of Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Computed Tomography (CT), Optical/Fluorescence and Ultrasound imaging. These technologies require advanced engineering and scientific skills for their development, usage and optimization. This suggests that in order to have an enhanced preclinical imaging infrastructure, we would require an advanced multidisciplinary collaboration and network between engineering and sciences. In order to facilitate this, we at Tehran University of Medical Sciences (TUMS) Preclinical Core Facility (TPCF) organized a symposium branded as TPIS (TPCF Preclinical Imaging Symposium). This was our 3rd annual symposium and it was on online platform due to Covid-19 pandemic. The symposium consisted of talks by domestic and international presenters from various disciplines of science and engineering. We are pleased that Frontiers in Biomedical Technology (FBT) is publishing these abstract in their journal. We at TPCF are also inviting the readers of FBT to attend our 4th annual TPIS (for more information visit our website on: www.TPCF.ir). Preclinical Core Facility Preclinical Imaging Medical technology In Frontiers in Biomedical Technologies Tehran University of Medical Sciences, 2020 7(2020), Supple1 (DE-627)815913818 (DE-600)2806579-7 23455837 nnns volume:7 year:2020 number:Supple1 https://doaj.org/article/9fe4ceb7db3f4426954fe316e1b5f67f kostenfrei https://fbt.tums.ac.ir/index.php/fbt/article/view/297 kostenfrei https://doaj.org/toc/2345-5837 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2020 Supple1 |
| allfieldsSound |
(DE-627)DOAJ064913082 (DE-599)DOAJ9fe4ceb7db3f4426954fe316e1b5f67f DE-627 ger DE-627 rakwb eng R855-855.5 3rd TPCF Preclinical Symposium Imaging (TPIS 2020) verfasserin aut 3rd TPCF Preclinical Symposium Imaging(TPIS 2020) 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The path of discovering/designing a molecule to developing a novel drug could take up to an average of 12 years and costs around $1 billion (USD). Preclinical phase is a major step on this path and is the part where scientists perform additional studies on their molecules prior to moving the drug into clinical studies. Preclinical studies consist of anything ranging from observing efficacy, dosing strategy, safety and toxicological studies and pharmacokinetics and pharmacodynamics. Pharmacodynamics consist of any studies performed in order to understand the relationship between the amount of drug in the body and its biological effect. In summary this means what does the drug do to the body and how potent and efficacious the drug is? In pharmacokinetics we are interested to identify the effect of body on the drug. Therefore, we would be interested in knowing the absorption, distribution, metabolism and excretion of the novel drug. In order to ensure reliability and consistency all of the preclinical results should be complied with the good laboratory practice and are required to be submitted to organization such as FDA before filing for approval of an investigational new drug. Addressing all of the above questions requires time and money but with the rise of cutting-edge technologies such as preclinical imaging, advancement of preclinical studies has excelled. This is due to being able to see in real time and in the same preclinical model the majority of parameters needed to be identified for preclinical phase of drug development. There are numerous dedicated preclinical imaging devices that could be used. These devices consists of Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Computed Tomography (CT), Optical/Fluorescence and Ultrasound imaging. These technologies require advanced engineering and scientific skills for their development, usage and optimization. This suggests that in order to have an enhanced preclinical imaging infrastructure, we would require an advanced multidisciplinary collaboration and network between engineering and sciences. In order to facilitate this, we at Tehran University of Medical Sciences (TUMS) Preclinical Core Facility (TPCF) organized a symposium branded as TPIS (TPCF Preclinical Imaging Symposium). This was our 3rd annual symposium and it was on online platform due to Covid-19 pandemic. The symposium consisted of talks by domestic and international presenters from various disciplines of science and engineering. We are pleased that Frontiers in Biomedical Technology (FBT) is publishing these abstract in their journal. We at TPCF are also inviting the readers of FBT to attend our 4th annual TPIS (for more information visit our website on: www.TPCF.ir). Preclinical Core Facility Preclinical Imaging Medical technology In Frontiers in Biomedical Technologies Tehran University of Medical Sciences, 2020 7(2020), Supple1 (DE-627)815913818 (DE-600)2806579-7 23455837 nnns volume:7 year:2020 number:Supple1 https://doaj.org/article/9fe4ceb7db3f4426954fe316e1b5f67f kostenfrei https://fbt.tums.ac.ir/index.php/fbt/article/view/297 kostenfrei https://doaj.org/toc/2345-5837 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 7 2020 Supple1 |
| language |
English |
| source |
In Frontiers in Biomedical Technologies 7(2020), Supple1 volume:7 year:2020 number:Supple1 |
| sourceStr |
In Frontiers in Biomedical Technologies 7(2020), Supple1 volume:7 year:2020 number:Supple1 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Preclinical Core Facility Preclinical Imaging Medical technology |
| isfreeaccess_bool |
true |
| container_title |
Frontiers in Biomedical Technologies |
| authorswithroles_txt_mv |
3rd TPCF Preclinical Symposium Imaging (TPIS 2020) @@aut@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
815913818 |
| id |
DOAJ064913082 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ064913082</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309043120.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ064913082</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9fe4ceb7db3f4426954fe316e1b5f67f</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R855-855.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">3rd TPCF Preclinical Symposium Imaging (TPIS 2020)</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">3rd TPCF Preclinical Symposium Imaging(TPIS 2020)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The path of discovering/designing a molecule to developing a novel drug could take up to an average of 12 years and costs around $1 billion (USD). Preclinical phase is a major step on this path and is the part where scientists perform additional studies on their molecules prior to moving the drug into clinical studies. Preclinical studies consist of anything ranging from observing efficacy, dosing strategy, safety and toxicological studies and pharmacokinetics and pharmacodynamics. Pharmacodynamics consist of any studies performed in order to understand the relationship between the amount of drug in the body and its biological effect. In summary this means what does the drug do to the body and how potent and efficacious the drug is? In pharmacokinetics we are interested to identify the effect of body on the drug. Therefore, we would be interested in knowing the absorption, distribution, metabolism and excretion of the novel drug. In order to ensure reliability and consistency all of the preclinical results should be complied with the good laboratory practice and are required to be submitted to organization such as FDA before filing for approval of an investigational new drug. Addressing all of the above questions requires time and money but with the rise of cutting-edge technologies such as preclinical imaging, advancement of preclinical studies has excelled. This is due to being able to see in real time and in the same preclinical model the majority of parameters needed to be identified for preclinical phase of drug development. There are numerous dedicated preclinical imaging devices that could be used. These devices consists of Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Computed Tomography (CT), Optical/Fluorescence and Ultrasound imaging. These technologies require advanced engineering and scientific skills for their development, usage and optimization. This suggests that in order to have an enhanced preclinical imaging infrastructure, we would require an advanced multidisciplinary collaboration and network between engineering and sciences. In order to facilitate this, we at Tehran University of Medical Sciences (TUMS) Preclinical Core Facility (TPCF) organized a symposium branded as TPIS (TPCF Preclinical Imaging Symposium). This was our 3rd annual symposium and it was on online platform due to Covid-19 pandemic. The symposium consisted of talks by domestic and international presenters from various disciplines of science and engineering. We are pleased that Frontiers in Biomedical Technology (FBT) is publishing these abstract in their journal. We at TPCF are also inviting the readers of FBT to attend our 4th annual TPIS (for more information visit our website on: www.TPCF.ir).</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Preclinical Core Facility</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Preclinical Imaging</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical technology</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Frontiers in Biomedical Technologies</subfield><subfield code="d">Tehran University of Medical Sciences, 2020</subfield><subfield code="g">7(2020), Supple1</subfield><subfield code="w">(DE-627)815913818</subfield><subfield code="w">(DE-600)2806579-7</subfield><subfield code="x">23455837</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:Supple1</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9fe4ceb7db3f4426954fe316e1b5f67f</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://fbt.tums.ac.ir/index.php/fbt/article/view/297</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2345-5837</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2020</subfield><subfield code="e">Supple1</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
3rd TPCF Preclinical Symposium Imaging (TPIS 2020) |
| spellingShingle |
3rd TPCF Preclinical Symposium Imaging (TPIS 2020) misc R855-855.5 misc Preclinical Core Facility misc Preclinical Imaging misc Medical technology 3rd TPCF Preclinical Symposium Imaging(TPIS 2020) |
| authorStr |
3rd TPCF Preclinical Symposium Imaging (TPIS 2020) |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)815913818 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
R855-855 |
| illustrated |
Not Illustrated |
| issn |
23455837 |
| topic_title |
R855-855.5 3rd TPCF Preclinical Symposium Imaging(TPIS 2020) Preclinical Core Facility Preclinical Imaging |
| topic |
misc R855-855.5 misc Preclinical Core Facility misc Preclinical Imaging misc Medical technology |
| topic_unstemmed |
misc R855-855.5 misc Preclinical Core Facility misc Preclinical Imaging misc Medical technology |
| topic_browse |
misc R855-855.5 misc Preclinical Core Facility misc Preclinical Imaging misc Medical technology |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Frontiers in Biomedical Technologies |
| hierarchy_parent_id |
815913818 |
| hierarchy_top_title |
Frontiers in Biomedical Technologies |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)815913818 (DE-600)2806579-7 |
| title |
3rd TPCF Preclinical Symposium Imaging(TPIS 2020) |
| ctrlnum |
(DE-627)DOAJ064913082 (DE-599)DOAJ9fe4ceb7db3f4426954fe316e1b5f67f |
| title_full |
3rd TPCF Preclinical Symposium Imaging(TPIS 2020) |
| author_sort |
3rd TPCF Preclinical Symposium Imaging (TPIS 2020) |
| journal |
Frontiers in Biomedical Technologies |
| journalStr |
Frontiers in Biomedical Technologies |
| callnumber-first-code |
R |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
txt |
| author_browse |
3rd TPCF Preclinical Symposium Imaging (TPIS 2020) |
| container_volume |
7 |
| class |
R855-855.5 |
| format_se |
Elektronische Aufsätze |
| author-letter |
3rd TPCF Preclinical Symposium Imaging (TPIS 2020) |
| title_sort |
3rd tpcf preclinical symposium imaging(tpis 2020) |
| callnumber |
R855-855.5 |
| title_auth |
3rd TPCF Preclinical Symposium Imaging(TPIS 2020) |
| abstract |
The path of discovering/designing a molecule to developing a novel drug could take up to an average of 12 years and costs around $1 billion (USD). Preclinical phase is a major step on this path and is the part where scientists perform additional studies on their molecules prior to moving the drug into clinical studies. Preclinical studies consist of anything ranging from observing efficacy, dosing strategy, safety and toxicological studies and pharmacokinetics and pharmacodynamics. Pharmacodynamics consist of any studies performed in order to understand the relationship between the amount of drug in the body and its biological effect. In summary this means what does the drug do to the body and how potent and efficacious the drug is? In pharmacokinetics we are interested to identify the effect of body on the drug. Therefore, we would be interested in knowing the absorption, distribution, metabolism and excretion of the novel drug. In order to ensure reliability and consistency all of the preclinical results should be complied with the good laboratory practice and are required to be submitted to organization such as FDA before filing for approval of an investigational new drug. Addressing all of the above questions requires time and money but with the rise of cutting-edge technologies such as preclinical imaging, advancement of preclinical studies has excelled. This is due to being able to see in real time and in the same preclinical model the majority of parameters needed to be identified for preclinical phase of drug development. There are numerous dedicated preclinical imaging devices that could be used. These devices consists of Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Computed Tomography (CT), Optical/Fluorescence and Ultrasound imaging. These technologies require advanced engineering and scientific skills for their development, usage and optimization. This suggests that in order to have an enhanced preclinical imaging infrastructure, we would require an advanced multidisciplinary collaboration and network between engineering and sciences. In order to facilitate this, we at Tehran University of Medical Sciences (TUMS) Preclinical Core Facility (TPCF) organized a symposium branded as TPIS (TPCF Preclinical Imaging Symposium). This was our 3rd annual symposium and it was on online platform due to Covid-19 pandemic. The symposium consisted of talks by domestic and international presenters from various disciplines of science and engineering. We are pleased that Frontiers in Biomedical Technology (FBT) is publishing these abstract in their journal. We at TPCF are also inviting the readers of FBT to attend our 4th annual TPIS (for more information visit our website on: www.TPCF.ir). |
| abstractGer |
The path of discovering/designing a molecule to developing a novel drug could take up to an average of 12 years and costs around $1 billion (USD). Preclinical phase is a major step on this path and is the part where scientists perform additional studies on their molecules prior to moving the drug into clinical studies. Preclinical studies consist of anything ranging from observing efficacy, dosing strategy, safety and toxicological studies and pharmacokinetics and pharmacodynamics. Pharmacodynamics consist of any studies performed in order to understand the relationship between the amount of drug in the body and its biological effect. In summary this means what does the drug do to the body and how potent and efficacious the drug is? In pharmacokinetics we are interested to identify the effect of body on the drug. Therefore, we would be interested in knowing the absorption, distribution, metabolism and excretion of the novel drug. In order to ensure reliability and consistency all of the preclinical results should be complied with the good laboratory practice and are required to be submitted to organization such as FDA before filing for approval of an investigational new drug. Addressing all of the above questions requires time and money but with the rise of cutting-edge technologies such as preclinical imaging, advancement of preclinical studies has excelled. This is due to being able to see in real time and in the same preclinical model the majority of parameters needed to be identified for preclinical phase of drug development. There are numerous dedicated preclinical imaging devices that could be used. These devices consists of Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Computed Tomography (CT), Optical/Fluorescence and Ultrasound imaging. These technologies require advanced engineering and scientific skills for their development, usage and optimization. This suggests that in order to have an enhanced preclinical imaging infrastructure, we would require an advanced multidisciplinary collaboration and network between engineering and sciences. In order to facilitate this, we at Tehran University of Medical Sciences (TUMS) Preclinical Core Facility (TPCF) organized a symposium branded as TPIS (TPCF Preclinical Imaging Symposium). This was our 3rd annual symposium and it was on online platform due to Covid-19 pandemic. The symposium consisted of talks by domestic and international presenters from various disciplines of science and engineering. We are pleased that Frontiers in Biomedical Technology (FBT) is publishing these abstract in their journal. We at TPCF are also inviting the readers of FBT to attend our 4th annual TPIS (for more information visit our website on: www.TPCF.ir). |
| abstract_unstemmed |
The path of discovering/designing a molecule to developing a novel drug could take up to an average of 12 years and costs around $1 billion (USD). Preclinical phase is a major step on this path and is the part where scientists perform additional studies on their molecules prior to moving the drug into clinical studies. Preclinical studies consist of anything ranging from observing efficacy, dosing strategy, safety and toxicological studies and pharmacokinetics and pharmacodynamics. Pharmacodynamics consist of any studies performed in order to understand the relationship between the amount of drug in the body and its biological effect. In summary this means what does the drug do to the body and how potent and efficacious the drug is? In pharmacokinetics we are interested to identify the effect of body on the drug. Therefore, we would be interested in knowing the absorption, distribution, metabolism and excretion of the novel drug. In order to ensure reliability and consistency all of the preclinical results should be complied with the good laboratory practice and are required to be submitted to organization such as FDA before filing for approval of an investigational new drug. Addressing all of the above questions requires time and money but with the rise of cutting-edge technologies such as preclinical imaging, advancement of preclinical studies has excelled. This is due to being able to see in real time and in the same preclinical model the majority of parameters needed to be identified for preclinical phase of drug development. There are numerous dedicated preclinical imaging devices that could be used. These devices consists of Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Computed Tomography (CT), Optical/Fluorescence and Ultrasound imaging. These technologies require advanced engineering and scientific skills for their development, usage and optimization. This suggests that in order to have an enhanced preclinical imaging infrastructure, we would require an advanced multidisciplinary collaboration and network between engineering and sciences. In order to facilitate this, we at Tehran University of Medical Sciences (TUMS) Preclinical Core Facility (TPCF) organized a symposium branded as TPIS (TPCF Preclinical Imaging Symposium). This was our 3rd annual symposium and it was on online platform due to Covid-19 pandemic. The symposium consisted of talks by domestic and international presenters from various disciplines of science and engineering. We are pleased that Frontiers in Biomedical Technology (FBT) is publishing these abstract in their journal. We at TPCF are also inviting the readers of FBT to attend our 4th annual TPIS (for more information visit our website on: www.TPCF.ir). |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| container_issue |
Supple1 |
| title_short |
3rd TPCF Preclinical Symposium Imaging(TPIS 2020) |
| url |
https://doaj.org/article/9fe4ceb7db3f4426954fe316e1b5f67f https://fbt.tums.ac.ir/index.php/fbt/article/view/297 https://doaj.org/toc/2345-5837 |
| remote_bool |
true |
| ppnlink |
815913818 |
| callnumber-subject |
R - General Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| callnumber-a |
R855-855.5 |
| up_date |
2024-07-04T00:49:32.842Z |
| _version_ |
1803607524343021568 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ064913082</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309043120.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ064913082</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9fe4ceb7db3f4426954fe316e1b5f67f</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R855-855.5</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">3rd TPCF Preclinical Symposium Imaging (TPIS 2020)</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">3rd TPCF Preclinical Symposium Imaging(TPIS 2020)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The path of discovering/designing a molecule to developing a novel drug could take up to an average of 12 years and costs around $1 billion (USD). Preclinical phase is a major step on this path and is the part where scientists perform additional studies on their molecules prior to moving the drug into clinical studies. Preclinical studies consist of anything ranging from observing efficacy, dosing strategy, safety and toxicological studies and pharmacokinetics and pharmacodynamics. Pharmacodynamics consist of any studies performed in order to understand the relationship between the amount of drug in the body and its biological effect. In summary this means what does the drug do to the body and how potent and efficacious the drug is? In pharmacokinetics we are interested to identify the effect of body on the drug. Therefore, we would be interested in knowing the absorption, distribution, metabolism and excretion of the novel drug. In order to ensure reliability and consistency all of the preclinical results should be complied with the good laboratory practice and are required to be submitted to organization such as FDA before filing for approval of an investigational new drug. Addressing all of the above questions requires time and money but with the rise of cutting-edge technologies such as preclinical imaging, advancement of preclinical studies has excelled. This is due to being able to see in real time and in the same preclinical model the majority of parameters needed to be identified for preclinical phase of drug development. There are numerous dedicated preclinical imaging devices that could be used. These devices consists of Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Computed Tomography (CT), Optical/Fluorescence and Ultrasound imaging. These technologies require advanced engineering and scientific skills for their development, usage and optimization. This suggests that in order to have an enhanced preclinical imaging infrastructure, we would require an advanced multidisciplinary collaboration and network between engineering and sciences. In order to facilitate this, we at Tehran University of Medical Sciences (TUMS) Preclinical Core Facility (TPCF) organized a symposium branded as TPIS (TPCF Preclinical Imaging Symposium). This was our 3rd annual symposium and it was on online platform due to Covid-19 pandemic. The symposium consisted of talks by domestic and international presenters from various disciplines of science and engineering. We are pleased that Frontiers in Biomedical Technology (FBT) is publishing these abstract in their journal. We at TPCF are also inviting the readers of FBT to attend our 4th annual TPIS (for more information visit our website on: www.TPCF.ir).</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Preclinical Core Facility</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Preclinical Imaging</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical technology</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Frontiers in Biomedical Technologies</subfield><subfield code="d">Tehran University of Medical Sciences, 2020</subfield><subfield code="g">7(2020), Supple1</subfield><subfield code="w">(DE-627)815913818</subfield><subfield code="w">(DE-600)2806579-7</subfield><subfield code="x">23455837</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:Supple1</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9fe4ceb7db3f4426954fe316e1b5f67f</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://fbt.tums.ac.ir/index.php/fbt/article/view/297</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2345-5837</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">2020</subfield><subfield code="e">Supple1</subfield></datafield></record></collection>
|
| score |
7.400463 |